Significant Efficacy: Among 25 patients treated with NEO100, 6 (24%) achieved significant radiographic remission, representing a 300% increase over the typical 8% response rate seen with salvage therapies, indicating NEO100's potential as an effective option for recurrent IDH1-mutant high-grade gliomas.
Survival Rate Improvement: 36% of patients demonstrated survival of 18 months or longer post-NEO100 treatment, showcasing the therapy's potential for long-term survival in heavily pretreated populations, which may shift treatment paradigms in this field.
No Significant Toxicity: The intranasal administration of NEO100 has shown no significant toxicity even with prolonged and chronic dosing, indicating a high safety profile that could enhance patient treatment experiences.
Expanded Clinical Data: The growing clinical cohort reinforces the treatment's effectiveness, bolstering confidence in NEO100 as a first-in-class CNS-penetrant metabolic therapy, potentially driving significant advancements in neuro-oncology.
NTHI
$9.88+Infinity%1D
Analyst Views on NTHI
About NTHI
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
